Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study.

MLA

Zhang, Ying, et al. “Lenvatinib Radiofrequency Ablation Sequential Therapy Offers Survival Benefits for Patients with Unresectable Hepatocellular Carcinoma at Intermediate Stage and the Liver Reserve of Child–Pugh A Category: A Multicenter Study.” Hepatology Research, vol. 54, no. 12, Dec. 2024, pp. 1174–92. EBSCOhost, https://doi.org/10.1111/hepr.14089.

APA

Zhang, Y., Numata, K., Imajo, K., Uojima, H., Funaoka, A., Komiyama, S., Ogushi, K., Chuma, M., Irie, K., Kokubu, S., Yoneda, M., Kobayashi, T., Hidaka, H., Fukushima, T., Kobayashi, S., Morimoto, M., Kagawa, T., Hattori, N., Watanabe, T., & Iwase, S. (2024). Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study. Hepatology Research, 54(12), 1174–1192. https://doi.org/10.1111/hepr.14089

Chicago

Zhang, Ying, Kazushi Numata, Kento Imajo, Haruki Uojima, Akihiro Funaoka, Satoshi Komiyama, Katsuaki Ogushi, et al. 2024. “Lenvatinib Radiofrequency Ablation Sequential Therapy Offers Survival Benefits for Patients with Unresectable Hepatocellular Carcinoma at Intermediate Stage and the Liver Reserve of Child–Pugh A Category: A Multicenter Study.” Hepatology Research 54 (12): 1174–92. doi:10.1111/hepr.14089.